1. Home
  2. ZKH vs ADCT Comparison

ZKH vs ADCT Comparison

Compare ZKH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$3.39

Market Cap

587.4M

Sector

N/A

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.72

Market Cap

483.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
ADCT
Founded
1998
2011
Country
China
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
483.1M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
ZKH
ADCT
Price
$3.39
$3.72
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
174.8K
965.0K
Earning Date
11-20-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,236,195,501.00
$75,209,000.00
Revenue This Year
$2.58
$10.36
Revenue Next Year
$10.62
$3.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.35
52 Week Low
$2.50
$1.05
52 Week High
$3.90
$4.80

Technical Indicators

Market Signals
Indicator
ZKH
ADCT
Relative Strength Index (RSI) 49.23 49.88
Support Level $3.09 $3.38
Resistance Level $3.56 $3.89
Average True Range (ATR) 0.22 0.18
MACD -0.03 0.03
Stochastic Oscillator 35.19 68.81

Price Performance

Historical Comparison
ZKH
ADCT

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: